Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis (Nasdaq: NUWE) announced the submission of the AVOID-HF clinical study analysis at the HFSA 2022 Annual Scientific Meeting, focusing on the superiority of ultrafiltration over diuretics in treating fluid overload in heart failure patients. The analysis utilized the Finkelstein-Schoenfeld method to enhance statistical precision, although the study was terminated early due to enrollment issues unrelated to patient safety. The company aims to establish Aquadex therapy as the standard care for diuretic-resistant heart failure patients and recently started its REVERSE-HF study.
Nuwellis, Inc. (NASDAQ: NUWE) will release its Q2 2022 financial results on August 9, 2022, followed by a conference call and webcast at 9:00 AM ET. The call aims to discuss the financial outcomes and provide a general business overview. Nuwellis focuses on developing the Aquadex SmartFlow® system for ultrafiltration therapy to assist patients with fluid overload. For additional details, visit the Investors page on their website.
Nuwellis, Inc. (Nasdaq: NUWE) recently hosted a webinar featuring leading clinicians discussing the effectiveness of Aquadex® ultrafiltration (UF) therapy for managing fluid overload in heart failure patients in outpatient settings. The panel emphasized the economic challenges of current care standards, highlighting that 24% of patients are readmitted within 30 days. Outpatient Aquadex therapy showed potential in reducing readmissions by up to 79% while improving patient satisfaction. The company aims to capitalize on this opportunity to enhance patient outcomes and reduce healthcare costs.
Nuwellis, Inc. (Nasdaq: NUWE) announced the enrollment of the first patient in its pivotal REVERSE-HF study, which will evaluate the efficacy of its Aquadex ultrafiltration therapy versus traditional IV diuretics for treating fluid overload in heart failure patients. Conducted across multiple sites in the U.S., the study aims to demonstrate improved patient outcomes and economic benefits, addressing the high readmission rates associated with heart failure. Key endpoints include mortality and heart failure events within 30 and 90 days, using innovative statistical methods to analyze results.
Nuwellis, Inc. (Nasdaq: NUWE) announced the expansion of its Aquadex SmartFlow® system to two new pediatric hospitals in Florida and Arkansas, highlighting a 36% CAGR in its pediatric segment. The device is specifically designed for gentle fluid removal in children suffering from fluid overload and is FDA-cleared for patients weighing over 20 kg. Additionally, Nuwellis is developing a new pediatric continuous renal replacement therapy device, supported by a $1.7 million NIH grant, aimed at improving care for small children with kidney issues.
Nuwellis, Inc. (NASDAQ: NUWE) announced the adjournment of its 2022 Annual Meeting of Stockholders, held on May 17, 2022, due to a lack of quorum. With only 49.23% of outstanding shares represented, the meeting will reconvene on May 25, 2022, at 2:00 p.m. Central Time to allow stockholders more time to vote on proposals outlined in the proxy statement filed on April 11, 2022. Stockholders of record as of March 30, 2022, are urged to vote before May 24, 2022, at 11:59 p.m. Eastern Time.
Nuwellis, Inc. (NUWE) reported a total revenue of $1.9 million for Q1 2022, marking a 17% increase from Q4 2021. This growth was driven by higher sales of consumables, despite capital equipment sales being lower than the previous year. The company received a Category III CPT Code effective January 1, 2022, enhancing reimbursement for therapeutic ultrafiltration and advancing Aquadex. Gross margin improved to 57.2%, while net loss decreased to $4.5 million. Cash reserves stood at approximately $19.3 million as of March 31, 2022.
Nuwellis (Nasdaq: NUWE) presented three Aquadex-related abstracts at the Pediatric Academic Societies meeting, held from April 21-25, 2022, in Denver. The research, partially funded by Nuwellis and the Ultrafiltration Therapy Registry, emphasizes the negative effects of fluid overload and the benefits of ultrafiltration therapy for pediatric patients. The Aquadex SmartFlow® system allows for precise fluid removal, critical for patients weighing 20 kg or more. CEO Nestor Jaramillo Jr. highlighted the research's importance in improving outcomes for those suffering from pediatric kidney disease.
Nuwellis, Inc. (NASDAQ: NUWE) announced that its Q1 2022 financial results will be released on May 10, 2022. The company will host a conference call at 9:00 AM ET to discuss the results and provide a business overview. Investors can access the live webcast through the Nuwellis website or dial in using the provided numbers. Nuwellis focuses on developing the Aquadex SmartFlow® system for ultrafiltration therapy, aimed at patients with fluid overload.
Nuwellis (Nasdaq: NUWE) has obtained IRB approval for its REVERSE-HF study, aimed at evaluating its Aquadex® ultrafiltration therapy against IV diuretics for heart failure patients with fluid overload. Over 1 million heart failure hospitalizations occur annually in the U.S., with 40% of these patients resistant to current treatments. The multicenter trial, beginning enrollment in 2022, will be led by prominent medical experts and seeks to affirm the therapeutic benefits of Aquadex, potentially transforming patient care.